Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ENO1 | P06733 | 2/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
| ▸ | POLG | P54098 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2458617 | 0.82 | BTN3A1 (0.60) | BTN3A1ALDH1A1ENO1PRKCAABCB11 | |
| SCHEMBL9891073 | 0.81 | BTN3A1 (0.54) | BTN3A1ALDH1A1ENO1PRKCAABCB11 | |
| SCHEMBL27602723 | 0.81 | BTN3A1 (0.54) | BTN3A1ALDH1A1ENO1PRKCAABCB11 | |
| SCHEMBL9891072 | 0.81 | BTN3A1 (0.58) | BTN3A1ALDH1A1ENO1PRKCAABCB11 | |
| SCHEMBL17039630 | 0.79 | BTN3A1 (0.53) | BTN3A1ALDH1A1ENO1PRKCAABCB11 | |
| SCHEMBL10378800 | 0.78 | BTN3A1 (0.50) | BTN3A1ALDH1A1ENO1PRKCAABCB11 | |
| SCHEMBL17533526 | 0.77 | FOLH1 (0.47) | BTN3A1 | |
| SCHEMBL17036739 | 0.76 | BTN3A1 (0.50) | BTN3A1ALDH1A1ENO1PRKCAABCB11 | |
| SCHEMBL10251138 | 0.76 | BTN3A1 (0.57) | BTN3A1ALDH1A1ENO1PRKCAABCB11 | |
| SCHEMBL3437081 | 0.76 | BTN3A1 (0.53) | BTN3A1ALDH1A1ENO1PRKCAABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239821-A1 | N-ACYL FOSMIDOMYCIN PRODRUG ANALOGS AS NOVEL ANTIINFECTIVE AGENTS | THE GEORGE WASHINGTON UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-20240239821-A1 | N-ACYL FOSMIDOMYCIN PRODRUG ANALOGS AS NOVEL ANTIINFECTIVE AGENTS | THE GEORGE WASHINGTON UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239821-A1 | N-ACYL FOSMIDOMYCIN PRODRUG ANALOGS AS NOVEL ANTIINFECTIVE AGENTS | PSPH, PGLS, DNPEP | BTN3A1 4476/4885ALDH1A1 3707/4885ENO1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.